The global critical limb ischemia drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors attributing to the growth of the market is the increasing prevalence of critical limb ischemia. The key factors that spur the risk of the critical limb ischemia disease include increasing geriatric population, who are more vulnerable to the development of these conditions, and others include obesity, smoking, sedentary lifestyle, diabetes, and increased blood pressure. In 2018, about 30 million people in the US had diabetes, as per the IDF (International Diabetes Federation). Further, in 2019, the total adult population in the US with diabetes was 31 million while in Canada was 2.8 million. The US has the largest population of children and adolescents with type 1 diabetes (175,900). Moreover, there were around 189,000 mortalities due to diabetes in the US in 2019, which represents one of the highest numbers of mortalities around the globe. 

Further, if the critical limb ischemia left untreated, it may necessitate the amputation of the specific limb. Therefore, to avoid complexities among the growing incidence of critical limb ischemia, the demand for critical limb ischemia drugs is anticipated to grow globally, thereby propelling the market growth. Furthermore, the growing government investments in the R&D programs related to the drug conducted by the pharmaceutical companies are boosting the market growth. However, the risk of drug failure and the cases of drug recalls are likely to be the major hindrances for the market growth.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drug Type

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Abbott Laboratories, and Sanofi S.A., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Critical Limb Ischemia Drug Market Report by Segment

By Drug Type

• Antiplatelet Drugs

• Antihypertensive Agents

• Lipid-Lowering Agents

• Others

By Application

• Hospital

• Clinic

• Others

Global Critical Limb Ischemia Drug Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa